29 terms
Evidence assessment
Terms describing how the Institute judges and reports the strength of evidence.
Controlled vocabulary
Glossary
195 defined terms across nine categories. Where a term is used in more than one sense, the entry says which sense the Institute uses.
§1Categories
22 terms
Statistics and inference
Terms describing how effects are estimated and how uncertainty is expressed.
17 terms
Outcomes and endpoints
Terms describing what a study measures and what the measurement supports.
35 terms
Analytical chemistry
Terms describing the determination of identity, purity, content and quality.
11 terms
Quality and documentation
Terms describing the documentary record of a manufactured material.
§2All terms
A20 terms
- Absence of evidence
- Absolute risk difference
- Active-controlled
- Acylation
- Adjudication
- Adsorption
- Adverse event
- Aggregation
- Agonist
- Allocation concealment
- Amendment log
- Amylin
- Amylin analogue
- Anchor outcome
- Antagonist
- Area postrema
- Assessment cycle
- ATC code
- Attrition
- Average mass
B5 terms
C15 terms
- Cardiovascular outcome trial
- CAS number
- Certainty of evidence
- Certificate of analysis
- Chromatographic purity
- Clearance
- Clinical outcome
- Comment period
- Comparator
- Composite endpoint
- Compounded preparation
- Confidence interval
- Corrections log
- Counter-ion
- Crossover
D14 terms
- Data monitoring committee
- Deamidation
- Declared interest
- Deletion sequence
- Desensitisation
- Discontinuation for adverse events
- Disposition
- Document identifier
- Dose-finding
- Dose–response
- Double-blind
- Downgrading
- DPP-4
- Dual agonist
E12 terms
- Early stopping
- Effect size
- Effectiveness
- Efficacy
- Enantiomeric purity
- Endotoxin
- Enzymatic degradation
- Estimand
- Event-driven
- Evidence of absence
- Evidence synthesis
- Exploratory endpoint
F5 terms
G5 terms
H4 terms
I15 terms
- I-squared
- Identity
- Illustrative
- Imprecision
- In-use period
- Inconsistency
- Incretin
- Indirect comparison
- Indirectness
- Integration window
- Intention to treat
- Interaction test
- Intercurrent event
- ISO 17025
- Isomerisation
K1 term
L3 terms
M13 terms
- MACE
- Maintenance dose
- Margin
- Marketing authorisation
- Mass balance
- Mass spectrometry
- Minimal clinically important difference
- Minimum data standard
- Missing data
- Moderate certainty
- Monoisotopic mass
- Multiple imputation
- Multiplicity
N9 terms
- Negative result
- Network meta-analysis
- Next review
- Non-inferiority
- Not assessed
- Not verified
- Notoriety bias
- Number needed to harm
- Number needed to treat
O8 terms
- Odds ratio
- Off-label
- Open-label
- Open-label extension
- Optimal information size
- Orthogonal method
- Overview of reviews
- Oxidation
P21 terms
- Partial agonist
- Patient-reported outcome
- Peptide content
- Peptide mapping
- Per protocol
- Permeation enhancer
- Pharmacovigilance
- Phase 1
- Phase 2
- Phase 3
- PICO
- Placebo-controlled
- Placebo-subtracted
- Plasma protein binding
- Point estimate
- Pragmatic trial
- Primary endpoint
- Programme record
- Proportional hazards
- Protocol registration
- Publication bias
R12 terms
- Random-effects model
- Randomisation
- Randomised withdrawal
- Ratification
- Reference standard
- Related substances
- Research use only
- Responder analysis
- Reverse-phase HPLC
- Risk of bias
- Risk ratio
- Run-in period
S17 terms
- Sample provenance
- Scoping review
- Secondary endpoint
- Selective outcome reporting
- Sensitivity analysis
- Serious adverse event
- Size-exclusion chromatography
- Stability-indicating
- Statistical significance
- Steady state
- Sterility
- Stratification
- Subgroup analysis
- Submitted-evidence log
- Summary of findings
- Surrogate outcome
- System suitability
T8 terms
- Tachyphylaxis
- Testing hierarchy
- Third-party testing
- Titration
- Tmax
- Transitivity
- Trifluoroacetate
- Triple agonist
U2 terms
V4 terms
W2 terms
Compound Evidence Institute · CEI institutional document · https://compoundevidence.com/glossary/ · retrieved 30 July 2026